This three days training module can be used to build capacity of service providers aiming to improve access to care and treatment for HIV positive people using drugs. It aims to present participants with a theoretical basis and practical models of building effective programmes on access to care and treatment for PWIDs, using community-based outreach services for marginalized groups as a platform.
These guidelines produced by the World Health Organisation aim to reduce the number of deaths from opioid overdose by providing evidence-based recommendations on the availability of naloxone for people likely to witness an opioid overdose along with advice on the resuscitation and post-resuscitation care of opioid overdose in the community.
Notes from the fourth meeting of the National Intelligence Network on the health harms associated with drug use, held in London on 4 June 2014. The meeting had a specific focus on hepatitis C. A series of presentations from PHE looked at prevalence, testing in prisons an modelling the impact of treatment. Further presentations from the field considered good practice in substance misuse settings from a hepatologist and a drug service point of view drug, including how workforce development can improve outcomes.
Notes from the fifth meeting of the National Intelligence Network on the health harms associated with drug use, held in London on 22nd October 2014. The meeting had a specific focus on drug harms and included an update on the activities of PHE, a breifing on nitrous oxide from DrugWatch, NPS drugs, drug harms for sex workers and links between drug use and domestic violence.
This annual national report from Public Health England describes trends in the extent of infections and associated risks and behaviours among people who injected drugs in the United Kingdom (UK) to the end of 2013.
This bulletin presents the latest figures from the Office for National Statistics (ONS) on deaths related to drug poisoning (involving both legal and illegal drugs) and drug misuse (involving illegal drugs) in England and Wales for the last five years (2009 to 2013).